Why IMU is a multi multi bagger, page-25343

Hi Ben, WMHB

I was thinking the same thing.. LC apparently mentioned a NDA. Could there be an announcement coming regarding this type of an approach to further funding? Very possible in the near future in my opinion.

"The approach taken by many biotechs is to out license drugs for which they anticipate receiving revenue for in the future to a Big Pharma or partner. The out licensing is in return for an upfront payment and then royalty payments as time goes by, when the drugs in question starts being administerd to and paid for by patients and their health funds down the track. The out licensing biotech company is often responsible for ensuring the drug meets the necessary endpoints in its clinical trial development and is ultimately approved by the FDA or regulatory authority in question (e’g., the TGA). Whilst the acquirer or licensing partner is responsible for the ongoing funding, manufacturing and the ultimate marketing of the drug".

Good Luck all. Keep positive!